Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
09:02am, Thursday, 16'th Feb 2023
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
SAGE Stock: 3.53% Increase Explanation
02:25am, Tuesday, 07'th Feb 2023
The stock price of SAGE Therapeutics Inc (NASDAQ: SAGE) increased by 3.53% in the most recent trading session. This is why.
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
06:30am, Thursday, 02'nd Feb 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
12:42pm, Monday, 16'th Jan 2023 Zacks Investment Research
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.
Biotech's Blockbuster Week: 3 Stocks to Watch
05:32pm, Friday, 13'th Jan 2023 Zacks Investment Research
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
08:25am, Thursday, 12'th Jan 2023 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
06:30am, Tuesday, 03'rd Jan 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company wi
Sage Therapeutics Could Be In For A Depressing FDA Review
07:00am, Tuesday, 13'th Dec 2022
Sage Therapeutics, Inc. completed its rolling submission to the FDA for zuranolone in two indications. Zuranolone is a better formulation of Sage Therapeutics' marketed postpartum drug.
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
09:48am, Thursday, 08'th Dec 2022 Zacks Investment Research
ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
03:27pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
01:16am, Wednesday, 07'th Dec 2022 Zacks Investment Research
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
09:49pm, Tuesday, 06'th Dec 2022
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Expert Ratings for Sage Therapeutics
06:04pm, Tuesday, 06'th Dec 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
06:30am, Wednesday, 23'rd Nov 2022
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company wi
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned
